KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma

Antoni Ribas(University of California, Los Angeles), F. Stephen Hodi(Dana-Farber Cancer Institute), Donald P. Lawrence(Massachusetts General Hospital), Victoria Atkinson(Greenslopes Private Hospital), Sachin Agarwal(Indiana University Health), Matteo S. Carlino(The University of Sydney), Rosalie Fisher(Auckland District Health Board), Georgina V. Long(The University of Sydney), Wilson H. Miller(Jewish General Hospital), Yinan Huang(Novartis (United States)), Blanca Homet Moreno(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Omid Hamid(Angeles Clinic and Research Institute)
Annals of Oncology
September 1, 2017
10.1093/annonc/mdx377.003
Cited by 36

Abstract

Related Papers

No related papers found

Powered by citation graph analysis